Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 3
2005 3
2007 1
2009 3
2010 2
2011 2
2012 4
2013 4
2014 10
2015 18
2016 5
2018 1
2019 3
2020 4
2021 12
2022 8
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A; NALA Investigators. Saura C, et al. Among authors: dai ms. J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17. J Clin Oncol. 2020. PMID: 32678716 Free PMC article. Clinical Trial.
Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model.
Tseng LM, Lau KY, Chen JL, Chu PY, Huang TT, Lee CH, Wang WL, Chang YY, Huang CT, Huang CC, Chao TC, Tsai YF, Lai JI, Dai MS, Liu CY. Tseng LM, et al. Among authors: dai ms. Exp Cell Res. 2023 Aug 1;429(1):113652. doi: 10.1016/j.yexcr.2023.113652. Epub 2023 May 18. Exp Cell Res. 2023. PMID: 37209991 Free article.
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Chen TW, Hsiao W, Dai MS, Lin CH, Chang DY, Chen IC, Wang MY, Chang SH, Huang SM, Cheng AL, Wu KW, Tan KT, Lu YS. Chen TW, et al. Among authors: dai ms. Breast Cancer Res Treat. 2023 Oct;201(3):377-385. doi: 10.1007/s10549-023-06967-3. Epub 2023 Jun 21. Breast Cancer Res Treat. 2023. PMID: 37344660 Free PMC article.
Isolated hypoglossal nerve paralysis.
Chen YG, Dai MS, Ho CL, Huang TC. Chen YG, et al. Among authors: dai ms. Am J Med. 2014 Oct;127(10):926-7. doi: 10.1016/j.amjmed.2014.03.040. Epub 2014 May 5. Am J Med. 2014. PMID: 24811553 No abstract available.
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.
Chen TW, Dai MS, Tseng LM, Chen SC, Chao TY, Chao TC, Chang YC, Chiu CF, Liu CT, Lin CH, Liu CY, Chen YF, Chang DY, Yu JC, Rau KM, Hsieh YY, Shen SC, Huang SM, Cheng AL, Lu YS. Chen TW, et al. Among authors: dai ms. JAMA Oncol. 2024 Mar 1;10(3):325-334. doi: 10.1001/jamaoncol.2023.5456. JAMA Oncol. 2024. PMID: 38127335 Clinical Trial.
Reconcilable differences: idiopathic antiphospholipid syndrome.
Chen YG, Peng CK, Dai MS, Lin TY, Chen YC. Chen YG, et al. Among authors: dai ms. Am J Med. 2015 May;128(5):471-4. doi: 10.1016/j.amjmed.2015.01.010. Epub 2015 Feb 2. Am J Med. 2015. PMID: 25656111 No abstract available.
Malignant bowel obstruction: A retrospective clinical analysis.
Chen JH, Huang TC, Chang PY, Dai MS, Ho CL, Chen YC, Chao TY, Kao WY. Chen JH, et al. Among authors: dai ms. Mol Clin Oncol. 2014 Jan;2(1):13-18. doi: 10.3892/mco.2013.216. Epub 2013 Nov 19. Mol Clin Oncol. 2014. PMID: 24649301 Free PMC article.
79 results